Tyra Biosciences Net Income Over Time
| TYRA Stock | USD 32.34 1.26 4.05% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Tyra Biosciences Performance and Tyra Biosciences Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Tyra Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding Tyra Biosciences requires distinguishing between market price and book value, where the latter reflects Tyra's accounting equity. The concept of intrinsic value—what Tyra Biosciences' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Tyra Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Tyra Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income Analysis
Compare Tyra Biosciences and related stocks such as Rezolute, Savara Inc, and Geron Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RZLT | (49.3 K) | (49.3 K) | (6.7 M) | (9.7 M) | (11.4 M) | (14.9 M) | (20.3 M) | (29.9 M) | (30.4 M) | (20.3 M) | (20.9 M) | (41.1 M) | (51.8 M) | (68.5 M) | (74.4 M) | (67 M) | (63.6 M) |
| SVRA | (3.7 M) | (13.3 M) | (15.6 M) | (21.5 M) | (28.7 M) | (39.8 M) | (10.9 M) | (29.8 M) | (61.5 M) | (78.2 M) | (49.6 M) | (43 M) | (38.1 M) | (54.7 M) | (95.9 M) | (86.3 M) | (82 M) |
| GERN | (10.7 M) | (96.9 M) | (68.9 M) | (38.4 M) | (35.7 M) | 46 K | (29.5 M) | (27.9 M) | (27 M) | (63.6 M) | (75.6 M) | (116.1 M) | (141.9 M) | (184.1 M) | (174.6 M) | (157.1 M) | (149.3 M) |
| DAWN | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (12.6 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (95.5 M) | (85.9 M) | (90.2 M) |
| KURA | (33.6 K) | (22.4 K) | (27 K) | (27.3 K) | (11 M) | (22.6 M) | (27.6 M) | (35.4 M) | (60.4 M) | (63.1 M) | (89.6 M) | (130.5 M) | (135.8 M) | (152.6 M) | (174 M) | (156.6 M) | (148.8 M) |
| MRVI | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (8.5 M) | 76.9 M | 182 M | 220.2 M | (119 M) | (144.8 M) | (130.4 M) | (123.8 M) |
| NBTX | (5.2 M) | (5.2 M) | (5.3 M) | (8.1 M) | (9.6 M) | (17 M) | (21.9 M) | (26.1 M) | (29.9 M) | (50.9 M) | (33.6 M) | (47 M) | (57 M) | (39.7 M) | (68.1 M) | (61.3 M) | (58.3 M) |
| PROK | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (79.6 M) | (26.7 M) | (55.1 M) | (108 M) | (35.5 M) | (61.2 M) | (70.4 M) | (73.9 M) |
| EYPT | (2.3 M) | (8.6 M) | (24.8 M) | (11.9 M) | (13.4 M) | 6.3 M | (21.5 M) | (18.5 M) | (53.2 M) | (56.8 M) | (45.4 M) | (58.4 M) | (102.3 M) | (70.8 M) | (130.9 M) | (117.8 M) | (111.9 M) |
Tyra Biosciences and related stocks such as Rezolute, Savara Inc, and Geron Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Tyra Biosciences financial statement analysis. It represents the amount of money remaining after all of Tyra Biosciences operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Tyra Biosciences | TYRA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 2656 State Street, |
| Exchange | NASDAQ Exchange |
USD 32.34
Check out Tyra Biosciences Performance and Tyra Biosciences Correlation. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Tyra Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.